A detailed history of Janney Montgomery Scott LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 58,604 shares of BCRX stock, worth $455,939. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,604
Previous 65,829 10.98%
Holding current value
$455,939
Previous $407,000 9.34%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$6.41 - $8.69 $46,312 - $62,785
-7,225 Reduced 10.98%
58,604 $445,000
Q2 2024

Jul 25, 2024

BUY
$4.13 - $6.79 $176,470 - $290,129
42,729 Added 184.97%
65,829 $407,000
Q1 2024

May 01, 2024

BUY
$4.89 - $7.65 $4,806 - $7,519
983 Added 4.44%
23,100 $117,000
Q4 2023

Feb 07, 2024

SELL
$4.98 - $6.77 $27,190 - $36,964
-5,460 Reduced 19.8%
22,117 $132,000
Q3 2023

Nov 08, 2023

BUY
$6.71 - $7.92 $4,697 - $5,544
700 Added 2.6%
27,577 $195,000
Q2 2023

Jul 26, 2023

BUY
$6.96 - $8.81 $36,609 - $46,340
5,260 Added 24.33%
26,877 $189,000
Q1 2023

Apr 28, 2023

BUY
$7.94 - $11.84 $3,573 - $5,328
450 Added 2.13%
21,617 $180,000
Q2 2022

Aug 03, 2022

SELL
$7.89 - $17.88 $31,560 - $71,520
-4,000 Reduced 15.89%
21,167 $221,000
Q4 2021

Jan 27, 2022

SELL
$11.18 - $15.46 $27,759 - $38,387
-2,483 Reduced 8.98%
25,167 $349,000
Q3 2021

Oct 29, 2021

BUY
$14.21 - $17.65 $28,420 - $35,300
2,000 Added 7.8%
27,650 $397,000
Q2 2021

Jul 26, 2021

BUY
$9.5 - $17.24 $4,750 - $8,620
500 Added 1.99%
25,650 $406,000
Q1 2021

Apr 27, 2021

SELL
$7.37 - $13.61 $30,585 - $56,481
-4,150 Reduced 14.16%
25,150 $256,000
Q4 2020

Jan 25, 2021

BUY
$3.37 - $8.61 $2,527 - $6,457
750 Added 2.63%
29,300 $218,000
Q3 2020

Nov 06, 2020

BUY
$3.43 - $5.53 $10,290 - $16,590
3,000 Added 11.74%
28,550 $98,000
Q2 2020

Jul 23, 2020

BUY
$1.9 - $5.61 $5,700 - $16,830
3,000 Added 13.3%
25,550 $122,000
Q1 2020

Apr 30, 2020

SELL
$1.6 - $4.11 $136 - $349
-85 Reduced 0.38%
22,550 $45,000
Q4 2019

Jan 21, 2020

SELL
$1.59 - $3.45 $5,088 - $11,040
-3,200 Reduced 12.39%
22,635 $78,000
Q2 2019

Jul 29, 2019

SELL
$2.91 - $9.15 $2,910 - $9,150
-1,000 Reduced 3.73%
25,835 $98,000
Q1 2019

Apr 30, 2019

SELL
$7.38 - $9.72 $2,214 - $2,916
-300 Reduced 1.11%
26,835 $218,000
Q4 2018

Feb 01, 2019

SELL
$6.51 - $9.6 $14,322 - $21,120
-2,200 Reduced 7.5%
27,135 $219,000
Q2 2018

Jul 24, 2018

BUY
$4.6 - $6.52 $2,300 - $3,260
500 Added 1.73%
29,335 $168,000
Q1 2018

Apr 19, 2018

SELL
$4.35 - $5.82 $8,265 - $11,058
-1,900 Reduced 6.18%
28,835 $138,000
Q4 2017

Feb 14, 2018

SELL
$4.16 - $5.33 $2,496 - $3,198
-600 Reduced 1.91%
30,735 $151,000
Q3 2017

Nov 15, 2017

BUY
$4.1 - $5.97 $128,473 - $187,069
31,335
31,335 $164,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.